Another study presents PROTACs that target the degradation of protein tyrosine kinase 6 (PTK6), consisting of CRBN and VHL E3 ubiquitin ligase ligands and a published PTK6 inhibitor, as a potential treatment for breast cancer [86]. The gene discussed is PTK6; the disease is breast carcinoma.